Danazol therapy in acquired idiopathic sideroblastic anemia
Other
OA: closed
CC0
⤵ 6 in-corpus citations
AI-generated summary
This study evaluated danazol therapy in six patients with acquired idiopathic sideroblastic anemia, finding no improvement in hemoglobin or platelet counts in any participant.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Danazol, a synthetic androgen, was used in the treatment of 6 patients with acquired idiopathic sideroblastic anemia. No patient had a response to therapy as determined by an increase in either the hemoglobin or platelet count.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (4)
- Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases 1994
- Therapeutic efficacy of danazol in myelodysplastic syndromes 1988
- Prolonged complete remission of myelodysplastic syndrome treated with danazol, retinoic acid and low-dose prednisone 2000
- Danazol in idiopathic sideroblastic anemia 2009
Cited by (4)
- Danazol in idiopathic sideroblastic anemia 2009
- Prolonged complete remission of myelodysplastic syndrome treated with danazol, retinoic acid and low-dose prednisone 2000
- Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases 1994
- Therapeutic efficacy of danazol in myelodysplastic syndromes 1988
Source provenance
- openalex
- last seen: 2026-05-13T18:27:55.367740+00:00
- pubmed
- last seen: 2026-10-08T21:24:31.663940+00:00
License: CC0
· commercial use OK